Adiponectin is Not Associated With Blood Pressure in Normotensives and Untreated Hypertensives With Normal Kidney Function

Abstract

The role of adiponectin in hypertension is still a matter of debate. Obtained conflicting results could be mostly explained with diversity of subjects included in different studies. Our aim was to analyze association of adiponectin with blood pressure (BP) in a group of normotensive and untreated hypertensive subjects.Participants (N = 257) were selected from a random sample of 2487 subjects enrolled in an observational cross-sectional study. Subjects with diabetes and chronic kidney diseases were excluded. BP was measured using Omron M6 device following ESH/ESC guidelines. Adiponectin concentration was determined by ELISA.There were no differences in adiponectin values (mg/L) between hypertensives and normotensives (median 9.75; iqr: 7.44–17.88 vs 11.35; iqr: 7.43–12.63; P = 0.17). On univariate linear regression adiponectin was not associated with systolic or diastolic BP (P > 0.05). Furthermore, multivariate analysis did not show significant contribution of log-transformed adiponectin either to systolic (β = −0.040; P = 0.43) or diastolic BP (β = 0.066; P = 0.33).In our group of normotensives and untreated hypertensives with normal kidney function adiponectin was not associated with BP even after adjustment for other risk factors. Our results and conclusions should not be extrapolated to subjects with other characteristics.

Plasma adiponectin in hypertensive patients with and without metabolic syndrome

“…On the other hand, reports consistent with the results of my study, i.e. showing no difference between adiponectin levels in patients with arterial hypertension and normotensive control subjects [31]. Different results being obtained in the studies of adiponectin's impact on blood pressure values may indirectly point to the complexity of the mechanisms behind the pathophysiology of essential arterial hypertension.…”

Adipose-Vascular Coupling and Potential Therapeutics

“…Endothelium-dependent vasodilation by adiponectin can result from NO release via activation of guanylyl cyclase (46)(47)(48)(49) and is disturbed in leptin receptor-deficient obesity and diabetes-for example, in Zucker diabetic fatty (fa/fa) rats (50). Although adiponectin clearly plays a role in endothelial dysfunction in diabetes and obesity, recent data question a pathogenic role of circulating adiponectin in human hypertension (51,52). This view is supported by findings demonstrating that chronic centrally administered adiponectin has no effects on heart rate and blood pressure in normotensive and hypertensive rats (53).…”

Adiponectin, blood pressure and hypertension - a narrative review

“…A year after the publication of this study, our group published a paper which did not show a difference in plasma adiponectin concentration between normotensives and hypertensives with normal renal function. 59 Taking into account the heterogeneity of studies included in this meta-analysis and the fact that over a fourth of the studies did not find an association of adiponectin and hypertension, the question arises of whether this association is the same in all populations and stages of hypertension and across the whole cardiometabolic continuum. This is especially interesting when noting that Mallamaci et al found a positive association of adiponectin and hypertension.…”